Mr. Market's non-response notwithstanding, Johnson & Johnson (NYSE:JNJ) turned in a great second quarter. But with any company as big as J&J, not every investor question can be answered, and sometimes the leftover question marks are pretty big.
Below are three crucial questions Motley Fool health care analysts Michael Douglass and David Williamson think J&J still needs to answer.
1 exciting growth stock with fewer question marks
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.